Loke J, Metzner M, Boucher R, Jackson A, et al. Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy. Br J Haematol 2022;196:368-373.
PMID: 34490623